@lfholt RC220 (E,E)-bisantrene (RCDS1)
Binds to DNA and RNA G-quadruplex structures which leads to a range of anticancer effects, but most importantly stopping the expression of the key cancer regulator MYC.
Composition of Matter patent lodged.
Racura Oncology ~$500M AUD market cap.